Definium Therapeutics Stock Market Value
| DFTX Stock | 16.90 0.65 4.00% |
| Symbol | Definium |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Definium Therapeutics. Projected growth potential of Definium fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Definium Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Definium Therapeutics is measured differently than its book value, which is the value of Definium that is recorded on the company's balance sheet. Investors also form their own opinion of Definium Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Definium Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Definium Therapeutics' market value can be influenced by many factors that don't directly affect Definium Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Definium Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Definium Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Definium Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Definium Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Definium Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Definium Therapeutics.
| 11/08/2025 |
| 02/06/2026 |
If you would invest 0.00 in Definium Therapeutics on November 8, 2025 and sell it all today you would earn a total of 0.00 from holding Definium Therapeutics or generate 0.0% return on investment in Definium Therapeutics over 90 days. Definium Therapeutics is related to or competes with Boston Beer, Black Rock, Altigen Communications, Darden Restaurants, and Molson Coors. Definium Therapeutics is entity of United States More
Definium Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Definium Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Definium Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.79 | |||
| Information Ratio | 0.0588 | |||
| Maximum Drawdown | 16.61 | |||
| Value At Risk | (4.86) | |||
| Potential Upside | 7.13 |
Definium Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Definium Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Definium Therapeutics' standard deviation. In reality, there are many statistical measures that can use Definium Therapeutics historical prices to predict the future Definium Therapeutics' volatility.| Risk Adjusted Performance | 0.0605 | |||
| Jensen Alpha | 0.2739 | |||
| Total Risk Alpha | 0.0856 | |||
| Sortino Ratio | 0.0646 | |||
| Treynor Ratio | 1.72 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Definium Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Definium Therapeutics February 6, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0605 | |||
| Market Risk Adjusted Performance | 1.73 | |||
| Mean Deviation | 3.23 | |||
| Semi Deviation | 3.64 | |||
| Downside Deviation | 3.79 | |||
| Coefficient Of Variation | 1435.95 | |||
| Standard Deviation | 4.16 | |||
| Variance | 17.29 | |||
| Information Ratio | 0.0588 | |||
| Jensen Alpha | 0.2739 | |||
| Total Risk Alpha | 0.0856 | |||
| Sortino Ratio | 0.0646 | |||
| Treynor Ratio | 1.72 | |||
| Maximum Drawdown | 16.61 | |||
| Value At Risk | (4.86) | |||
| Potential Upside | 7.13 | |||
| Downside Variance | 14.34 | |||
| Semi Variance | 13.22 | |||
| Expected Short fall | (3.73) | |||
| Skewness | 0.045 | |||
| Kurtosis | 1.27 |
Definium Therapeutics Backtested Returns
Definium Therapeutics appears to be slightly risky, given 3 months investment horizon. Definium Therapeutics secures Sharpe Ratio (or Efficiency) of 0.17, which denotes the company had a 0.17 % return per unit of risk over the last 3 months. By reviewing Definium Therapeutics' technical indicators, you can evaluate if the expected return of 0.67% is justified by implied risk. Please utilize Definium Therapeutics' Coefficient Of Variation of 1435.95, downside deviation of 3.79, and Mean Deviation of 3.23 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Definium Therapeutics holds a performance score of 13. The firm shows a Beta (market volatility) of 0.16, which means not very significant fluctuations relative to the market. As returns on the market increase, Definium Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Definium Therapeutics is expected to be smaller as well. Please check Definium Therapeutics' downside variance, and the relationship between the total risk alpha and daily balance of power , to make a quick decision on whether Definium Therapeutics' price patterns will revert.
Auto-correlation | 0.64 |
Good predictability
Definium Therapeutics has good predictability. Overlapping area represents the amount of predictability between Definium Therapeutics time series from 8th of November 2025 to 23rd of December 2025 and 23rd of December 2025 to 6th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Definium Therapeutics price movement. The serial correlation of 0.64 indicates that roughly 64.0% of current Definium Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.64 | |
| Spearman Rank Test | 0.59 | |
| Residual Average | 0.0 | |
| Price Variance | 2.81 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Definium Stock Analysis
When running Definium Therapeutics' price analysis, check to measure Definium Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Definium Therapeutics is operating at the current time. Most of Definium Therapeutics' value examination focuses on studying past and present price action to predict the probability of Definium Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Definium Therapeutics' price. Additionally, you may evaluate how the addition of Definium Therapeutics to your portfolios can decrease your overall portfolio volatility.